‘Molecules, Madness, and Malaria’ (Pythagoras Press) is available as a paperback and Kindle eBook on Amazon. Link: https://lnkd.in/gcTShrV
In 1856, William Henry Perkin, an 18 year old chemistry student in London, was attempting to synthesize quinine, when instead he ended up with a dark sticky substance in the bottom of his test tube. When cleaning it out with alcohol, he produced a bright purple liquid, which became aniline purple, the first synthetic fabric dye, and inadvertently launched an industry. Within the next few years, about 30 companies appeared, using synthetic organic chemistry to make dyes, and later over the years paints, cosmetics, agricultural chemicals, food coloring—and medicines. Among these were medicines for psychiatry and infectious diseases, particularly malaria, which at the time was devastating the development of a worldwide empire.
These efforts were not in isolation, but intertwined, culminating in the appearance in the 1950s of a failed antimalarial, chlorpromazine (Thorazine), which revolutionized care of psychotic patients. Sulfa drugs, derived from a red azo dye, became the building blocks on one of the trails to the first antidepressants. A penicillin preservative became meprobamate, the first blockbuster tranquilizer. Later, benzodiazepine tranquilizers were created from fabric dyes their inventor had previously discarded as a student.
The role of dye-derived synthetic drugs in medicine continues to this day, as indigo and related dyes are being developed for treating infections and cancer. Methylene blue, discovered 150 years ago, is now being studied for Alzheimer’s disease. This story is as old as seventeenth century missionaries discovering medicinal leaves in the high Andes, and as new as today’s headlines. In this book, Dr. Mendelson uses his 40 years of experience in pharmacology to describe the little-known history of the intertwined efforts to find treatments for psychiatric illness and infectious disease.